Search

Your search keyword '"Perrotta, S."' showing total 813 results
Start Over Author "Perrotta, S."
813 results on '"Perrotta, S."'

101. ACE-536 INCREASES HEMOGLOBIN LEVELS IN ADULTS WITH BETA-THALASSEMIA: PRELIMINARY RESULTS FROM A PHASE 2 STUDY

Author

Piga, A., Melpignano, A., Perrotta, S., Borgna-Pignatti, C., Caruso, V., Voskaridou, E., Filosa, A., Aydinok, Y., Condon, C., Wilson, D., Sherman, M., Attie, K., and Ege Üniversitesi

Subjects
education, social sciences, humanities, geographic locations, health care economics and organizations
Abstract

19th Congress of the European-Hematology-Association -- JUN 12-15, 2014 -- Milan, ITALY, WOS: 000342830901113, European Hematol Assoc

Published
2014

102. Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization: A Webthal(R) Study

Author

Derchi, G, Galanello, R, Bina, P, Cappellini, Md, Piga, Antonio Giulio, Lai, Me, Quarta, A, Casu, G, Perrotta, S, Pinto, V, Musallam, Km, Forni, Gl, and on behalf of the Webthal® Pulmonary Arterial Hypertension Group

Subjects
Adult, Male, Right heart catheterization, Cardiac Catheterization, medicine.medical_specialty, Hypertension, Pulmonary, Thalassemia, Pulmonary arterial pressure, Jet velocity, Predictive Value of Tests, Risk Factors, Physiology (medical), Internal medicine, Prevalence, medicine, Humans, Familial Primary Pulmonary Hypertension, In patient, Pulmonary Wedge Pressure, Pulmonary wedge pressure, business.industry, beta-Thalassemia, Middle Aged, medicine.disease, Confidence interval, Surgery, Cross-Sectional Studies, Logistic Models, Echocardiography, Case-Control Studies, Multivariate Analysis, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Large group
Abstract

Background— Pulmonary arterial hypertension (PAH) remains a concern in patients with β-thalassemia major (TM) and intermedia (TI); however, studies evaluating its prevalence and risk factors using systematic confirmation on right heart catheterization are lacking. Methods and Results— This was a multicenter cross-sectional study of 1309 Italian β-thalassemia patients (mean age 36.4±9.3 years; 46% men; 74.6% TM, 25.4% TI). Patients with a tricuspid-valve regurgitant jet velocity ≥3.2 m/s (3.6%) on transthoracic echocardiography further underwent right heart catheterization to confirm the diagnosis of PAH (mean pulmonary arterial pressure ≥25 mm Hg and pulmonary capillary wedge pressure ≤15mm Hg). The confirmed PAH prevalence on right heart catheterization was 2.1% (95% confidence interval [CI], 1.4–3.0) and was higher in TI (4.8%; 95% CI, 3.0–7.7) than TM (1.1%; 95% CI, 0.6–2.0). The positive predictive value for the tricuspid-valve regurgitant jet velocity ≥3.2 m/s threshold for the diagnosis of pulmonary hypertension was 93.9%. Considerable functional limitation and decrease in the 6-minute walk distance were noted in patients with confirmed PAH. On multivariate logistic regression analysis, independent risk factors for confirmed PAH were age (odds ratio, 1.102 per 1-year increase; 95% CI, 1.06–1.15) and splenectomy (odds ratio, 9.31; 95% CI, 2.57–33.7). Conclusions— The prevalence of PAH in β-thalassemia patients as confirmed on right heart catheterization was 2.1%, with an ≈5-fold higher prevalence in TI than TM. Advanced age and splenectomy are risk factors for PAH in this patient population. Clinical Trial Registration— URL: http://www.ClinicalTrials.gov . Unique identifier: NCT01496963.

Published
2014

104. DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION)

Author

Ayidinok, Y., Kattamis, A., Cappellini, M. D., Beshlawy, A. E., Origa, R., Elalfy, M., Kilinc, Y., Perrotta, S., Karakas, Z., Viprakasit, V., Musallam, K., Constantinovici, N., Shen, J., Porter, J. B., and Ege Üniversitesi

Subjects
education, social sciences, humanities, geographic locations, health care economics and organizations
Abstract

19th Congress of the European-Hematology-Association -- JUN 12-15, 2014 -- Milan, ITALY, WOS: 000342830901110, European Hematol Assoc

Published
2014

105. The Italian SurveY on carDiac rEhabilitation 2008 (ISYDE 2008): study presentation

Author

Tramarin R., Ambrosetti M., De Feo S., Griffo R., Maslowsky F., Diaco T., Riccio C., Carlon R., Castello A., Ferratini M., Schweiger C., Chieffo C., Ciglia C., Lapolla A., Pietropaolo F., Furgi G., Martin G., Semprini P., Avallone A., Bertoli D., Belardinelli R., Soffiantino F., Scrutinio D., Maxia P., Coco R., Giustarini C., Anniboletti P., Favretto G., Vaghi P., Calisi P., Chiavetta C., Guarracini L., Marcellini G., Iannopollo M., Borello G., Matta M., Peccerillo N., Boncompagni . F, Amici A., Feraco E., Pulitanò G., Tripodi E., Capomolla S., Golino P., Parrilli G., Di Patria A., Di Gioia C., Micieli D., Perrotta S., Rubino A., Aulitto V., Riccio G., Codec L., Coruzzi P., Violi E., Nardini M., Urbinati S., Dcruz S., Piepoli M., Fucili A., Cerulli M., Roberto B., Balestra G., Tuniz D., Gori P., Marini R., Morgera T., Di Mario F., Volterrani M., Galati A., Salustri A., Jesi A.P., Lacch A., Loperfido F., Corsiglia L., Pantaleo P., Gigli G., Marchesi D., Febo O., Cobelli F., Malinverni C., Jones N., Anzà C., Frizelli R., Gei P., Acquistapace F., Pedretti R., Carugo S., Malfatto G., Meloni C., Giordano A., Schizzarotto A., Zanettini R., Bosco R., Occhi G., Aglieri S., Caprioli G., Cuocina N., Lazzaroni L., Laurenzi A., Savonelli C., Veniani M., Corda G., Meinecke C., Castiglioni G., Ravizza P., Giani P., Robustelli F., Gullace G., Passoni F., Barelli M.V., Richichi I., Rossi A., Politi A., Persico M., Giannuzzi P., Mazzucco G., Bosimini E., Riva G., Massobrio N., Gondoni L., Aina F., Ingignoli B., Cal M.V., Costante A., Villella M., La Rosa C., Sannia L., Barbanto P., Rametta R., Albanese D., Circo A., Raciti R., Scarnato L., Dispensa F., La Spina L., Stuto A., Vasco C., Gibiino S., Gabriele M., Dispensieri C., Carini V., Provvidenza M., Scalzini A., Macchi C., Fattirolli F., Vannucci M., Iacopetti L., Cordoni M., Gabriele F., Santoni R., Pitscheider W., Bettini R., Mandorla S., Anniboletti F., Patriarchi F., Baroni P.L., Bordin F., Biondi P., Bellotto F., Zanocco A., Ponchia A., Mantovani E., Li Greci E., Celegon L., Baracchi S., Pizzolato G., Peroni L., Apolloni E., Mosele G., Guarniero M., Roncon L., VIGORITO, CARLO, Tramarin, R., Ambrosetti, M., De Feo, S., Griffo, R., Maslowsky, F., Diaco, T., Riccio, C., Carlon, R., Castello, A., Ferratini, M., Schweiger, C., Chieffo, C., Vigorito, Carlo, Ciglia, C., Lapolla, A., Pietropaolo, F., Furgi, G., Martin, G., Semprini, P., Avallone, A., Bertoli, D., Belardinelli, R., Soffiantino, F., Scrutinio, D., Maxia, P., Coco, R., Giustarini, C., Anniboletti, P., Favretto, G., Vaghi, P., Calisi, P., Chiavetta, C., Guarracini, L., Marcellini, G., Iannopollo, M., Borello, G., Matta, M., Peccerillo, N., Boncompagni., F, Amici, A., Feraco, E., Pulitanò, G., Tripodi, E., Capomolla, S., Golino, P., Parrilli, G., Di Patria, A., Di Gioia, C., Micieli, D., Perrotta, S., Rubino, A., Aulitto, V., Riccio, G., Codec, L., Coruzzi, P., Violi, E., Nardini, M., Urbinati, S., Dcruz, S., Piepoli, M., Fucili, A., Cerulli, M., Roberto, B., Balestra, G., Tuniz, D., Gori, P., Marini, R., Morgera, T., Di Mario, F., Volterrani, M., Galati, A., Salustri, A., Jesi, A. P., Lacch, A., Loperfido, F., Corsiglia, L., Pantaleo, P., Gigli, G., Marchesi, D., Febo, O., Cobelli, F., Malinverni, C., Jones, N., Anzà, C., Frizelli, R., Gei, P., Acquistapace, F., Pedretti, R., Carugo, S., Malfatto, G., Meloni, C., Giordano, A., Schizzarotto, A., Zanettini, R., Bosco, R., Occhi, G., Aglieri, S., Caprioli, G., Cuocina, N., Lazzaroni, L., Laurenzi, A., Savonelli, C., Veniani, M., Corda, G., Meinecke, C., Castiglioni, G., Ravizza, P., Giani, P., Robustelli, F., Gullace, G., Passoni, F., Barelli, M. V., Richichi, I., Rossi, A., Politi, A., Persico, M., Giannuzzi, P., Mazzucco, G., Bosimini, E., Riva, G., Massobrio, N., Gondoni, L., Aina, F., Ingignoli, B., Cal, M. V., Costante, A., Villella, M., La Rosa, C., Sannia, L., Barbanto, P., Rametta, R., Albanese, D., Circo, A., Raciti, R., Scarnato, L., Dispensa, F., La Spina, L., Stuto, A., Vasco, C., Gibiino, S., Gabriele, M., Dispensieri, C., Carini, V., Provvidenza, M., Scalzini, A., Macchi, C., Fattirolli, F., Vannucci, M., Iacopetti, L., Cordoni, M., Gabriele, F., Santoni, R., Pitscheider, W., Bettini, R., Mandorla, S., Anniboletti, F., Patriarchi, F., Baroni, P. L., Bordin, F., Biondi, P., Bellotto, F., Zanocco, A., Ponchia, A., Mantovani, E., Li Greci, E., Celegon, L., Baracchi, S., Pizzolato, G., Peroni, L., Apolloni, E., Mosele, G., Guarniero, M., and Roncon, L.

Subjects
Heart Failure, Male, Internet, Time Factors, Heart Diseases, Cardiologia Riabilitativa, Data Collection, Myocardial Infarction, Rehabilitation Centers, Factor IX, Prevenzione secondaria, Italy, Risk Factors, Health Care Surveys, Practice Guidelines as Topic, Humans, Female, Longitudinal Studies, Public Health, ISYDE 2008, Coronary Artery Bypass, Follow-Up Studies
Abstract

In this paper, the Italian Society of Cardiac Rehabilitation and Prevention (GICR) presents the third survey on the status of cardiac rehabilitation (CR) in Italy. The Italian SurveY on carDiac rEhabilitation 2008 (ISYDE 2008) is a multicenter, observational study aimed at identifying the number and characteristics of Italian CR facilities, both in terms of health operators and interventions. Clinical records of all patients consecutively discharged within the whole network--composed of up to 200 CR units--from January 28 to February 10, 2008 will also be reviewed for diagnosis of admission, comorbidities, rehabilitation programs, and drug therapy, in order to obtain a snapshot of current implementation strategies in daily clinical practice. The survey will adopt a web-based methodology for data provision and transmission. Preliminary results of the survey are expected in the late summer 2008.

Published
2008

106. XQ-100: A legacy survey of one hundred 3.5 ≲z≲ 4.5 quasars observed with VLT/X-shooter

Author

López, S., primary, D’Odorico, V., additional, Ellison, S. L., additional, Becker, G. D., additional, Christensen, L., additional, Cupani, G., additional, Denney, K. D., additional, Pâris, I., additional, Worseck, G., additional, Berg, T. A. M., additional, Cristiani, S., additional, Dessauges-Zavadsky, M., additional, Haehnelt, M., additional, Hamann, F., additional, Hennawi, J., additional, Iršič, V., additional, Kim, T.-S., additional, López, P., additional, Lund Saust, R., additional, Ménard, B., additional, Perrotta, S., additional, Prochaska, J. X., additional, Sánchez-Ramírez, R., additional, Vestergaard, M., additional, Viel, M., additional, and Wisotzki, L., additional

Published
2016
Full Text
View/download PDF

109. Nature and statistical properties of quasar associated absorption systems in the XQ-100 Legacy Survey

Author

Perrotta, S., primary, D'Odorico, V., additional, Prochaska, J. X., additional, Cristiani, S., additional, Cupani, G., additional, Ellison, S., additional, López, S., additional, Becker, G. D., additional, Berg, T. A. M., additional, Christensen, L., additional, Denney, K. D., additional, Hamann, F., additional, Pâris, I., additional, Vestergaard, M., additional, and Worseck, G., additional

Published
2016
Full Text
View/download PDF

112. La dissezione ascellare con tecnica miniinvasiva

Author

Procaccini E, RUGGIERO, Roberto, Falco P, DOCIMO, Giovanni, GUBITOSI, Adelmo, Cimmino F, Perrotta S, Piazza P, Lo Schiavo F., Procaccini, E, Ruggiero, Roberto, Falco, P, Docimo, Giovanni, Gubitosi, Adelmo, Cimmino, F, Perrotta, S, Piazza, P, and Lo Schiavo, F.

Published
2003

115. [Septic complications of gallbladder lacerations during laparoscopic cholecystectomy]

Author

MANDATO M, RUGGIERO, Roberto, CORSALE I, PERROTTA S, ZENONE P, DE MARTINO A, RIPA C, GUIDA A, PROCACCINI F, PROCACCINI, Eugenio, Mandato, M, Ruggiero, Roberto, Corsale, I, Perrotta, S, Zenone, P, DE MARTINO, A, Ripa, C, Guida, A, Procaccini, F, and Procaccini, Eugenio

Subjects
Adult, Male, Cholecystectomy, Laparoscopic, Sepsis, Gallbladder, Humans, Female, Middle Aged, Intraoperative Complications, Aged
Abstract

The iatrogenic gallbladder perforation with bile and, eventually, gallstones loss in the peritoneal cavity happens in the laparoscopic cholecystectomies more frequently than in the laparotomic ones. The authors have reviewed their experience and recent bibliography with the aim to clarify factors that increase risks for this adverse effect; 579 patients subjected to laparoscopic cholecistectomy: in 81 cases (13.98%) the intra-peritoneal perforation of the gallbladder wall has happened, in 26 associated to gallstones loss; 12 of these last have developed abdominal wall infections. No case of intra-peritoneal abscess was observed. The Authors believe to be proper to select patients with the clinical and instrumental evaluation. They identify emergency and flogosis as risk factors for the perforations, as well the systemic illnesses for sepsis. They emphasize the role of antibiotic prophylaxis in the high risk subjects.

Published
2001

116. Clinical and molecular evaluation of non-dominant hereditary spherocytosis

Author

Miraglia del Giudice E, Nobili B, Francese M, D'Urso L, Eber S, Perrotta S., IOLASCON, ACHILLE, MIRAGLIA DEL GIUDICE, Emanuele, Nobili, Bruno, Francese, M, D'Urso, L, Iolascon, A, Eber, S, Perrotta, Silverio, Miraglia del Giudice, E, Nobili, B, Iolascon, Achille, and Perrotta, S.

Subjects
Ankyrins, Male, Adolescent, Genotype, Spectrin, Genes, Recessive, Spherocytosis, Hereditary, spherocytosi, de novo mutation, Pedigree, Phenotype, Child, Preschool, Mutation, Humans, Female, Child, Promoter Regions, Genetic
Abstract

About 75% of hereditary spherocytosis (HS) patients have the autosomal dominant form of the disease, whereas both parents of the remaining HS patients are clinically and haematologically normal. These patients could have either the autosomal recessive form of the disease or a de novo mutation. We studied 80 randomly chosen, Italian HS children with normal parents. They had different clinical phenotypes (16 mild, 40 moderate, 16 moderately severe and eight severe). These patients were screened for the occurrence of ankyrin or beta-spectrin de novo mutations. To search for ankyrin de novo mutations affecting mRNA accumulation, we studied a (AC)(n) microsatellite located in the non-coding sequence of the last exon of the ankyrin gene, and four different exonic polymorphisms in the beta-spectrin gene were utilized for the detection of de novo mutations influencing beta-spectrin mRNA stability. They were also screened for the presence of alpha-spectrin(LEPRA) as well as for the mutation -108T-->C in the ankyrin promoter, two variants previously found in some cases of genuinely recessive HS. Twenty-five patients showed ankyrin de novo mutations and 10 HS subjects had beta-spectrin de novo mutations. Furthermore, we found five patients to be heterozygous for alpha-spectrin(LEPRA) and one heterozygous for the mutation in the ankyrin promoter. Therefore, a molecular diagnosis was achieved in about 50% of the cases. Our data demonstrate that, among HS patients with normal parents, de novo dominant mutants are six times more common than recessive mutations. These results should be considered in view of the genetic counselling of a normal couple with a HS child.

Published
2001

119. MINIMALLY INVASIVE AXILLARY NODE DISSECTION

Author

Procaccini E, RUGGIERO, Roberto, Ferrara A, De Martino A, Perrotta S, Zenone P, Mandato M., Procaccini, E, Ruggiero, Roberto, Ferrara, A, De Martino, A, Perrotta, S, Zenone, P, and Mandato, M.

Published
2001

123. Clinical and Laboratory Features of of 103 Patients From 42 Italian Families with Inherited Thrimbocytopenia Derived from the Monoallelic Ala156Val Mutation of GPIb Alpha (Bolzano Mutation)

Author

Balduini, C., Perrotta, S., Bottega, R., Pecci, A., Melazzini, F., Civaschi, E., Russo, S., Magrin, S., Loffredo, G., Di Salvo, V., Russo, G., Casale, M., De Rocco, D., Grignani, C., Cattaneo, M., Baronci, C., Dragani, A., Albano, V., Jankovic, M., Scianguetta, S., Savoia, A., Noris, P., Brian Cannon, C., Balduini, S., Perrotta, Bottega, Roberta, A., Pecci, F., Melazzini, E., Civaschi, S., Russo, S., Magrin, G., Loffredo, V., Di Salvo, G., Russo, M., Casale, DE ROCCO, Daniela, C., Grignani, M., Cattaneo, C., Baronci, A., Dragani, V., Albano, M., Jankovic, S., Scianguetta, Savoia, Anna, and P., Noris

Subjects
GPIb-alpha Bolzano mutations Bernard-Soulier syndrome Mutational screening
Published
2011

124. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

Author

Porter, Jb, Lin, Kh, Beris, P, Forni, Gl, Taher, A, Habr, D, Domokos, G, Roubert, B, Thein, Sl, EPIC study investigators including Agaoglu, L, Alimena, G, Alonso, D, Ame, S, Angelucci, E, Arrizabalaga, B, Athanasiou Metaxa, M, Augustson, B, Aydinok, Y, Baba, A, Baccarani, M, Beck, J, Beyne Rauzy, O, Birgens, H, Bordessoule, D, Borgna Pignatti, C, Bosly, A, Bouabdallah, K, Bowen, D, Bron, D, Cappellini, Md, Capra, M, Cartron, G, Cazzola, M, Chalkias, C, Chan, Ll, Chancharunee, S, Chapman, C, Charoenkwan, P, Chasapopoulou, E, Cheze, S, Chuansumrit, A, Cianciulli, P, Dauriac, C, Delforge, M, Dölken, G, Dombret, H, Duyster, J, Economopoulos, T, Ehninger, G, Elalfy, M, El Beshlawy, A, Enggaard, L, Fenaux, P, Fillet, G, Filosa, A, Galanello, R, Ganser, A, Gastl, G, Gattermann, N, Giraudier, S, Goldfarb, A, Grigg, A, Guerci Bresler, A, Gumruk, F, Ha, Sy, Haase, D, Heinrich, B, Hertzberg, M, Ho, J, Hsu, Hc, Huang, S, Hunault Berger, M, Inusa, B, Jalumes, D, Jensen, J, Kattamis, A, Kilinc, Y, Kim, Kh, Kinsey, S, Kjeldsen, L, Koren, A, Lai, Me, Lai, Y, Lee, Jw, Lee, Kh, Lee, Sh, Legros, L, Li, C, Li, Ck, Li, Q, Linkesch, W, Lübbert, M, Lutz, D, Mohamed Thalha AJ, Mufti, G, Muus, P, Nobile, F, Ozsahin, H, Papadopoulos, N, Perrotta, S, Petrini, M, Pfeilstöcker, M, Piga, Antonio Giulio, Poole, J, Pungolino, E, Quarta, G, Ravoet, C, Remacha, Af, Rose, C, Roy, L, Saglio, Giuseppe, Sanz, G, Schmid, M, Schmugge, M, Schots, H, Secchi, G, Seymour, Jf, Shah, F, Shah, H, Shen, Z, Slama, B, Sutcharitchan, P, Tamary, H, Taylor, K, Tesch, Hj, Troncy, J, Vassilieff, D, Villegas, A, Viprakasit, V, Wainwright, L, Wassmann, B, Wettervald, M, Will, A, Wörmann, B, Wright, J, Yeh, Sp, Yoon, Ss, Zoumbos, Nc, Zweegman, S., Ozsahin, Ayse Hulya, Porter, Jb, Lin, Kh, Beris, P, Forni, Gl, Taher, A, Habr, D, Domokos, G, Roubert, B, Thein, Sl, on behalf of the EPIC study, Investigator, and Perrotta, Silverio

Subjects
safety, Male, Iron Overload, Adolescent, iron chelation therapy, Iron, Iron Chelating Agents/therapeutic use, Iron Chelating Agents, Benzoates, Anemia/drug therapy, Humans, Blood Transfusion, Benzoates/therapeutic use, Child, Iron/blood, ddc:616, ddc:618, iron overload, rare anaemias, serum ferritin, Ferritins/blood, Anemia, Original Articles, Triazoles, Deferasirox, Child, Preschool, Ferritins, rare anaemia, Female, Triazoles/therapeutic use
Abstract

Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation therapy are similar, irrespective of the underlying condition. However, data are limited for rare transfusiondependent anaemias, and it remains to be elucidated if response differs, depending on whether the anaemia has a primary haemolytic or production mechanism. Methods: The efficacy and safety of deferasirox (Exjade) in rare transfusion-dependent anaemias were evaluated over 1 yr, with change in serum ferritin as the primary efficacy endpoint. Initial deferasirox doses were 10–30 mg⁄ kg ⁄ d, depending on transfusion requirements; 34 patients had production anaemias, and 23 had haemolytic anaemias. Results: Patients with production anaemias or haemolytic anaemias had comparable transfusional iron-loading rates (0.31 vs. 0.30 mL red blood cells ⁄ kg ⁄ d), mean deferasirox dosing (19.3 vs. 19.0 mg⁄ kg ⁄ d) and baseline median serum ferritin (2926 vs. 2682 ng ⁄ mL). Baseline labile plasma iron (LPI) levels correlated significantly with the transfusional iron-loading rates and with serum ferritin levels in both cohorts. Reductions in median serum ferritin levels were initially faster in the production than the haemolytic anaemias, but at 1 yr, similar significant reductions of 940 and 617 ng ⁄mL were attained, respectively ()26.0% overall). Mean LPI decreased significantly in patients with production (P < 0.0001) and haemolytic (P = 0.037) anaemias after the first dose and was maintained at normal mean levels (

Published
2011

126. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up

Author

Cappellini, M.D. Bejaoui, M. Agaoglu, L. Canatan, D. Capra, M. Cohen, A. Drelichman, G. Economou, M. Fattoum, S. Kattamis, A. Kilinc, Y. Perrotta, S. Piga, A. Porter, J.B. Griffel, L. Dong, V. Clark, J. Aydinok, Y.

Abstract

Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66.8% completed the study; 43 patients (7.7%) discontinued because of adverse events. In patients with ≥ 4 years' deferasirox exposure who had liver biopsy, mean liver iron concentration significantly decreased by 7.8 ± 11.2 mg Fe/g dry weight (dw; n = 103; P < .001) and 3.1 ± 7.9 mg Fe/g dw (n = 68; P < .001) in the deferasirox and crossover cohorts, respectively. Median serum ferritin significantly decreased by 706 ng/mL (n = 196; P < .001) and 371 ng/mL (n = 147; P < .001), respectively, after ≥ 4 years'exposure. Investigator-assessed, drug-related adverse events, including increased blood creatinine (11.2%), abdominal pain (9.0%), and nausea (7.4%), were generally mild to moderate, transient, and reduced in frequency over time. No adverse effect was observed on pediatric growth or adolescent sexual development. This first prospective study of long-term deferasirox use in pediatric and adult patients with β- thalassemia suggests treatment for ≤ 5 years is generally well tolerated and effectively reduces iron burden. This trial was registered at www.clinicaltrials-.gov as #NCT00171210. © 2011 by The American Society of Hematology.

Published
2011

127. On a problem of potential wells

Author

Cellina, A, Perrotta, S, CELLINA, ARRIGO, Perrotta, S., Cellina, A, Perrotta, S, CELLINA, ARRIGO, and Perrotta, S.

Published
1995

130. Linfectomia ascellare con tecnica miniinvasiva

Author

RUGGIERO, Roberto, Ferrara A, Foglia E, Mandato M, Perrotta S, Procaccini E., Ruggiero, Roberto, Ferrara, A, Foglia, E, Mandato, M, Perrotta, S, and Procaccini, E.

Published
1999

133. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Author

Lee, Jw, Yoon, Ss, Shen, Zx, Ganser, A, Hsu, Hc, Habr, D, Domokos, G, Roubert, B, Porter, Jb, Agaoglu, L, Alimena, G, Alonso, D, Ame, S, Angelucci, E, Arrizabalaga, B, Athanasiou Metaxa, M, Augustson, B, Aydinok, Y, Baba, A, Baccarani, M, Beck, J, Beris, P, Beyne Rauzy, O, Birgens, H, Bordessoule, D, Borgna, Caterina, Bosly, A, Bouabdallah, K, Bowden, D, Bowen, D, Bron, D, Cappellini, Md, Capra, M, Cartron, G, Cazzola, M, Chalkias, C, Chan, Ll, Chancharunee, S, Chapman, C, Charoenkwan, P, Chasapopoulou, E, Cheze, S, Chuansumrit, A, Cianciulli, P, Dauriac, C, Delforge, M, Dölken, G, Dombret, H, Duyster, J, Economopoulos, T, Ehninger, G, Elalfy, M, El Beshlawy, A, Enggaard, L, Fenaux, P, Fillet, G, Filosa, A, Forni, G, Galanello, R, Gastl, G, Gattermann, N, Giraudier, S, Goldfarb, A, Grigg, A, Guerci Bresler, A, Gumruk, F, Ha, Sy, Haase, D, Heinrich, B, Hertzberg, M, Ho, J, Huang, S, Hunault Berger, M, Inusa, B, Jaulmes, D, Jensen, J, Kattamis, A, Kilinc, Y, Kim, Kh, Kinsey, S, Kjeldsen, L, Koren, A, Lai, Me, Lai, Y, Lee, Kh, Lee, Sh, Legros, L, Li, C, Li, Ck, Li, Q, Lin, Kh, Linkesch, W, Lübbert, M, Lutz, D, Mohamed Thalha AJ, Mufti, G, Muus, P, Nobile, F, Papadopoulos, N, Perrotta, S, Petrini, M, Pfeilstöcker, M, Piga, A, Poole, J, Pungolino, E, Quarta, G, Ravoet, C, Remacha, Af, Rose, C, Roy, L, Saglio, G, Sanz, G, Schmid, M, Schmugge, M, Schots, H, Secchi, G, Seymour, Jf, Shah, F, Shah, H, Shen, Z, Slama, B, Sutcharitchan, P, Taher, A, Tamary, H, Taylor, K, Tesch, Hj, Thein, Sl, Troncy, J, Vassilieff, D, Villegas, A, Viprakasit, V, Wainwright, L, Wassmann, B, Wettervald, M, Will, A, Wörmann, B, Wright, J, Yeh, Sp, Zoumbos, Nc, Zweegman, S., Lee, Jw, Yoon, S, Shen, Zx, Ganser, A, Hsu, Hc, Habr, D, Domokos, G, Roubert, B, Porter, Jb, EPIC study, Investigator, and Perrotta, Silverio

Subjects
Male, Biochemistry, Gastroenterology, Benzoates, beta-thalassemia, chemistry.chemical_compound, overloaded patients, oxidative stress, Prospective Studies, Prospective cohort study, pathophysiology, Beta thalassemia, complications, epidemiology, labile plasma iron, myelodysplastic syndromes, serum ferritin, transfusion-dependent anemias, Anemia, Aplastic, Hematology, Middle Aged, Tolerability, Creatinine, Iron chelation, Female, medicine.drug, Adult, medicine.medical_specialty, aplastic anemia, Adolescent, Anemia, Immunology, Iron Chelating Agents, Young Adult, Internal medicine, medicine, Humans, Aplastic anemia, therapy, business.industry, Myelodysplastic syndromes, Deferasirox, deferasirox, Cell Biology, Triazoles, medicine.disease, Chelation Therapy, Surgery, chemistry, Ferritins, business
Abstract

The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased significantly from 3254 ng/mL at baseline to 1854 ng/mL (P < .001). Decreases occurred in chelation-naive (3229-1520 ng/mL; P < .001, last-observation-carried-forward analysis), and previously chelated (3263-2585 ng/mL; P = .21, last-observation-carried-forward analysis) patients and were reflective of dose adjustments and ongoing iron intake. Baseline labile plasma iron levels were within normal range despite high serum ferritin levels. The most common drug-related adverse events were nausea (22%) and diarrhea (16%). Serum creatinine increases more than 33% above baseline and the upper limit of normal occurred in 29 patients (25%), but there were no progressive increases; concomitant use of cyclosporine had a significant impact on serum creatinine levels. The decrease in mean alanine aminotransferase levels at 1 year correlated significantly with reduction in serum ferritin (r = 0.40, P < .001). Mean absolute neutrophil and platelet counts remained stable during treatment, and there were no drug-related cytopenias. This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia. This study was registered at www.clinicaltrials.gov as #NCT00171821.

Published
2010

134. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N. Finelli, C. Della Porta, M. Fenaux, P. Ganser, A. Guerci-Bresler, A. Schmid, M. Taylor, K. Vassilieff, D. Habr, D. Domokos, G. Roubert, B. Rose, C. Agaoglu, L. Alimena, G. Alonso, D. Ame, S. Angelucci, E. Arrizabalaga, B. Athanasiou-Metaxa, M. Augustson, B. Aydinok, Y. Baba, A. Baccarani, M. Beck, J. Beris, P. Beyne-Rauzy, O. Birgens, H. Bordessoule, D. Borgna-Pignatti, C. Bosly, A. Bouabdallah, K. Bowden, D. Bowen, D. Bron, D. Cappellini, M.D. Capra, M. Cartron, G. Cazzola, M. Chalkias, C. Chan, L.L. Chancharunee, S. Chapman, C. Charoenkwan, P. Chasapopoulou, E. Cheze, S. Chuansumrit, A. Cianciulli, P. Dauriac, C. Delforge, M. Dölken, G. Dombret, H. Duyster, J. Economopoulos, T. Ehninger, G. Elalfy, M. El-Beshlawy, A. Enggaard, L. Fillet, G. Filosa, A. Forni, G. Galanello, R. Gastl, G. Giraudier, S. Goldfarb, A. Grigg, A. Gumruk, F. Ha, S.Y. Haase, D. Heinrich, B. Hertzberg, M. Ho, J. Hsu, H.-C. Huang, S. Hunault-Berger, M. Inusa, B. Jaulmes, D. Jensen, J. Kattamis, A. Kilinc, Y. Kim, K.-H. Kinsey, S. Kjeldsen, L. Koren, A. Lai, M.E. Lai, Y. Lee, J.-W. Lee, K.-H. Lee, S.-H. Legros, L. Li, C. Li, C.-K. Li, Q. Lin, K.-H. Linkesch, W. Lübbert, M. Lutz, D. Mohamed Thalha, A.J. Mufti, G. Muus, P. Nobile, F. Papadopoulos, N. Perrotta, S. Petrini, M. Pfeilstöcker, M. Piga, A. Poole, J. Porter, J.B. Pungolino, E. Quarta, G. Ravoet, C. Jolimont Lobbes, H.H. Remacha, A.F. Roy, L. Saglio, G. Sanz, G. Schmugge, M. Schots, H. Secchi, G. Seymour, J.F. Shah, F. Shah, H. Shen, Z. Slama, B. Sutcharitchan, P. Taher, A. Tamary, H. Tesch, H.-J. Thein, S.L. Troncy, J. Villegas, A. Viprakasit, V. Wainwright, L. Wassmann, B. Wettervald, M. Will, A. Wörmann, B. Wright, J. Yeh, S.-P. Yoon, S.-S. Zoumbos, N.C. Zweegman, S.

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

135. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B., Rose, C., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Cappellini, M. D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chan, L. L., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Elalfy, M., El Beshlawy, A., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Giraudier, S., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kattamis, A., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, J. W., Lee, K. H., Lee, S. H., Legros, L., Li, C., C. K., Li, Li, Q., Lin, K. H., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Seymour, J. F., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Taher, A., Tamary, H., Tesch, H. J., Thein, S. L., Troncy, J., Villegas, A., Viprakasit, V., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., Zweegman, S., Gattermann, N, Finelli, C, Porta, Md, Fenaux, P, Ganser, A, GUERCI BRESLER, A, Schmid, M, Taylor, K, Vassilieff, D, Habr, D, Domokos, G, Roubert, B, Rose, C, EPIC study, Investigator, Perrotta, Silverio, Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, Baccarani M, EPIC study investigators., and Çukurova Üniversitesi

Subjects
Male, Pediatrics, Cancer Research, Blood transfusion, Thalassemia, medicine.medical_treatment, Gastroenterology, Benzoates, Child, Hematology, biology, Benzoic Acids, Alanine Transaminase, Adolescent, Adult, Aged, Blood Transfusion, Preschool, Female, Ferritins, Humans, Iron Chelating Agents, Iron Overload, Middle Aged, Myelodysplastic Syndromes, Triazoles, Young Adult, Oncology, Child, Preschool, medicine.drug, medicine.medical_specialty, Myelodysplastic syndromes, deferasirox, iron chelation therapy, labile plasma iron, myelodysplastic syndromes, serum ferritin, Serum ferritin, Deferasirox, Iron chelation therapy, Labile plasma iron, Internal medicine, medicine, Adverse effect, iron-overloaded patients, transfusion, Labile plasmairon, business.industry, medicine.disease, Discontinuation, Iron chelationtherapy, Alanine transaminase, biology.protein, business, Myelodysplastic syndrome
Abstract

PubMedID: 20451251 The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ~50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

136. GROWTH AND DEVELOPMENT OF PAEDIATRIC PATIENTS WITH BETATHALASSAEMIA TREATED WITH DEFERASIROX FOR UP TO 5 YEARS

Author

Aydinok, Y., Agaoglu, L., Bejaoui, M., Canatan, D., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., Kilinc, Y., Perrotta, S., Griffel, L., Lagrone, D., Clark, J., Cappellini, M. D., and Ege Üniversitesi

Subjects
health services administration, population characteristics, geographic locations
Abstract

15th Annual Meeting of the European-Hematology-Association -- JUN 10-13, 2010 -- Barcelona, SPAIN, WOS: 000279051301361, European Hematol Assoc

Published
2010

138. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Author

Cappellini, M. D., Porter, J., El Beshlawy, A., C. K., Li, Seymour, J. F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J. W., Chan, L. L., Lin, K. H., Rose, C., Taher, A., Thein, S. L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, K. H., Lee, S. H., Legros, L., Li, C., Li, Q., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Tamary, H., Tesch, H. J., Troncy, J., Villegas, A., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., and Zweegman, S.

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Blood transfusion, Iron Overload, Adolescent, Anemia, Thalassemia, medicine.medical_treatment, Iron chelation therapy, Transfusion medicine, Transfusion-dependent anemias, Hemosiderosis, Iron Chelating Agents, Gastroenterology, Benzoates, Young Adult, IRON CHELATION, Internal medicine, medicine, Humans, Blood Transfusion, Tissue Distribution, SERUM FERRITIN, Chelation therapy, Prospective Studies, Child, Aged, Aged, 80 and over, business.industry, Myelodysplastic syndromes, Deferasirox, Hematology, Middle Aged, Triazoles, medicine.disease, DEFERASOROX, Deferoxamine, Child, Preschool, Ferritins, Female, Original Article, business, TRANSFUSION-DEPENDENT ANEMIAS, Iron, Dietary, medicine.drug
Abstract

Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron intake, with dose titration guided by serum ferritin trends and safety markers, provides clinically acceptable chelation in patients (agedor=2 years) with transfusional hemosiderosis from various types of anemia.The recommended initial dose was 20 mg/kg/day for patients receiving 2-4 packed red blood cell units/month and 10 or 30 mg/kg/day was recommended for patients receiving less or more frequent transfusions, respectively. Dose adjustments were based on 3-month serum ferritin trends and continuous assessment of safety markers. The primary efficacy end-point was change in serum ferritin after 52 weeks compared with baseline.The 1744 patients enrolled had the following conditions; thalassemia (n=1115), myelodysplastic syndromes (n=341), aplastic anemia (n=116), sickle cell disease (n=80), rare anemias (n=43) and other transfused anemias (n=49). Overall, there was a significant reduction in serum ferritin from baseline (-264 ng/mL; P0.0001), reflecting dosage adjustments and ongoing iron intake. The most common (5%) adverse events were gastrointestinal disturbances (28%) and skin rash (10%). Conclusions Analysis of this large, prospectively collected data set confirms the response to chelation therapy across various anemias, supporting initial deferasirox doses based on transfusional iron intake, with subsequent dose titration guided by trends in serum ferritin and safety markers (clinicaltrials.gov identifier: NCT00171821).

Published
2009

139. Obstruction of the right coronary artery ostium due to acute aortic dissection

Author

Patanè, S, Marte, F, Lentini, S, Monaco, F, Perrotta, S, DI BELLA, Gianluca, Patanè, F, Gaeta, Roberto, and Monaco, Francesco

Subjects
Thorax, Aortic dissection, Acute coronary syndrome, medicine.medical_specialty, business.industry, Vascular disease, medicine.disease, Chest pain, Acute aortic dissection, Ascending aortic aneurysm, Chest pain, Aortic aneurysm, Aneurysm, Right coronary artery, medicine.artery, Internal medicine, medicine, Cardiology, Radiology, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Acute aortic dissection presents with a wide range of manifestations and it is frequently confused with acute coronary syndrome, leading to delayed diagnosis and inappropriate treatment. A high clinical index of suspicion is necessary. Longstanding arterial hypertension, elevated D-dimer levels and new onset atypical chest pain can help the clinician to perform a difficult differential diagnosis. We present a case of acute aortic dissection in a 68-year-old Italian woman with longstanding arterial hypertension, unknown ascending aortic aneurysm, normal D-dimer levels, new onset atypical chest pain and electrocardiographic images mimicking acute coronary syndrome. Also this case focuses attention on the importance of a correct evaluation of new onset chest pain.

Published
2009

141. Interpreting siliciclastic-carbonate detrital modes in Foreland Basin Systems: an example from Upper Miocene arenites of the Central Apennines, Italy. In: Sedimentary Provenance: Petrographic and Geochemical Perspectives

Author

Critelli S., La Pera E., Galluzzo F., Milli S., Moscatelli M., Perrotta S., and Santantonio M.

Abstract

In the centrai Apennines, interacting siliciclastic and carbonate marine clastic wedges filled the foreland basin system during the late Miocene. Conjunction of collisional thrust tectonics and prethrusting norma) faults generated a complex foredeep with intrabasinal structural highs that represented additional source areas to the basin. Detrital modes of the late Miocene centrai Apennines orogenic system range in composition from intrabasinal carbonate to quartzofeldspatholithic and calclithite arenites. The external zone of the foredeep is characterized by hemipelagic deposits, called the Orbulina Mari. Their arenite beds are composed by intrabasinal carbonate, with dominant bioclasts and minor intraclasts, and glauconite derived from an active shallow-marine carbonate source. These hemipelagic deposits are partly coeval with an d partly overlain by siliciclastic turbidites of the Frosinone an d the ArgillosoArenacea Formations, and they represent deposition within local foredeep depocenters. Siliciclastic turbidite sandstones are quartzofeldspatholithic, which documents provenances from metamorphic, plutonic, ophiolitic, and sedimentary rocks. Carbonate intrabasinal structural highs were the main source for carbonate breccias, intrabasinal arenites, and calclithites ofthe Brecce della Renga Formation, the deposits of which are locally interbedded with the coeval siliciclastic turbidite sandstones. Evolution of late Miocene sandstone detrital modes reflected the changing nature of the centrai Apennines thrust belt through time an d the complex architecture of the foreland basin system; it records the history of accretion, deformation of the foredeep, and progressive areai reduction of carbonate-producing areas along with the sedimentary an d structural evolution of local intrabasinal highs.

Published
2007

142. The Italian survey on hereditary spherocytosis

Author

Pinto, L, Iolascon, A., Matarese, S. M. R., Nobili, B, Perrotta, S., MIRAGLIA DEL GIUDICE, Emanuele, Pinto, L, Iolascon, A., MIRAGLIA DEL GIUDICE, Emanuele, Matarese, S. M. R., Nobili, B, and Perrotta, S.

Published
1995

143. On a problem of potential wells

Author

CELLINA, ARRIGO, Perrotta, S., Cellina, A, and Perrotta, S

Subjects
dirichlet problems, Minimizer for an energy functional, differential inclusions, rotations of matrices, differential inclusion, potential well, MAT/05 - ANALISI MATEMATICA, Implicit partial differential equations
Published
1995

144. Erythroid membrame proteomic

Author

Orru', Stefania, Caterino, M, Ruoppolo, M, Savoia, M, Perrotta, S, Salvatore, F, and Iolascon, A.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results